Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

• DOI: 10.1073/pnas.1819745116
• Publication Date: 2019-04-16T00:26:00Z
• Authors: Jie Xu; Li-Juan Chen; Shuang-Shuang Yang; Yan Sun; Wen Wu; Yuan-Fang Liu; Ji Xu; Yan Zhuang; Wu Zhang; Xiang-Qin Weng; Jing Wu; Yan Wang; Jin Wang; Hua Yan; Wen-Bin Xu; Hua Jiang; Juan Du; Xiao-Yi Ding; Biao Li; Jun-Min Li; Wei-Jun Fu; Jiang Zhu; Li Zhu; Zhu Chen; Xiao-Hu (Frank) Fan; Jian Hou; Jian-Yong Li; Jian-Qing Mi; Sai-Juan Chen
• Keywords: Cytokine Release Syndrome; Refractory (planetary science)

Significance Multiple myeloma (MM) is one of the most common hematological malignancies. Developing an effective treatment strategy for refractory/relapsed (R/R) MM represents a major challenge. In this trial, 17 R/R patients, who had previously experienced multiple lines treatments, received chimeric antigen receptor modified T (CAR T) cell preparation targeting two epitopes BCMA, and remarkable overall response 88.2% was achieved. This work confirms feasibility importance CAR therapy in patients with MM. Meanwhile, adverse events encountered study are analyzed, providing reference other studies. We also suggest that can eventually be combined therapeutics to treat newly diagnosed achieving better result future trials.